254 related articles for article (PubMed ID: 16026266)
41. A thirty year journey in the polyol pathway.
Kinoshita JH
Exp Eye Res; 1990 Jun; 50(6):567-73. PubMed ID: 2115448
[TBL] [Abstract][Full Text] [Related]
42. Aldose reductase inhibitors and late complications of diabetes.
Benfield P
Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
[TBL] [Abstract][Full Text] [Related]
43. Potential use of aldose reductase inhibitors to prevent diabetic complications.
Zenon GJ; Abobo CV; Carter BL; Ball DW
Clin Pharm; 1990 Jun; 9(6):446-57. PubMed ID: 2114249
[TBL] [Abstract][Full Text] [Related]
44. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
[TBL] [Abstract][Full Text] [Related]
45. A non-invasive, multi-target approach to treat diabetic retinopathy.
Julius A; Hopper W
Biomed Pharmacother; 2019 Jan; 109():708-715. PubMed ID: 30551523
[TBL] [Abstract][Full Text] [Related]
46. In Search of Differential Inhibitors of Aldose Reductase.
Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
[TBL] [Abstract][Full Text] [Related]
47. Polymorphisms of the aldose reductase locus (ALR2) and susceptibility to diabetic microvascular complications.
Patel A; Ratanachaiyavong S; Millward BA; Demaine AG
Adv Exp Med Biol; 1993; 328():325-32. PubMed ID: 8493909
[No Abstract] [Full Text] [Related]
48. On the pathogenesis of diabetic retinopathy. A 1990 update.
Frank RN
Ophthalmology; 1991 May; 98(5):586-93. PubMed ID: 1905795
[TBL] [Abstract][Full Text] [Related]
49. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
Costantino L; Rastelli G; Vianello P; Cignarella G; Barlocco D
Med Res Rev; 1999 Jan; 19(1):3-23. PubMed ID: 9918192
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
[TBL] [Abstract][Full Text] [Related]
51. Polyol pathway and protein kinase C activity of rat Schwannoma cells.
Kamiya H; Nakamura J; Hamada Y; Nakashima E; Naruse K; Kato K; Yasuda Y; Hotta N
Diabetes Metab Res Rev; 2003; 19(2):131-9. PubMed ID: 12673781
[TBL] [Abstract][Full Text] [Related]
52. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
53. [Enzymological Studies on the Mechanisms of Pathogenesis of Diabetic Complications].
Tanimoto T
Yakugaku Zasshi; 2018; 138(3):405-415. PubMed ID: 29503433
[TBL] [Abstract][Full Text] [Related]
54. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy.
Dagher Z; Park YS; Asnaghi V; Hoehn T; Gerhardinger C; Lorenzi M
Diabetes; 2004 Sep; 53(9):2404-11. PubMed ID: 15331552
[TBL] [Abstract][Full Text] [Related]
55. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Robison WG; Nagata M; Laver N; Hohman TC; Kinoshita JH
Invest Ophthalmol Vis Sci; 1989 Nov; 30(11):2285-92. PubMed ID: 2509395
[TBL] [Abstract][Full Text] [Related]
56. [Pathogenesis and therapeutic targets of diabetic microvascular complications].
Li H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 May; 35(3):233-7. PubMed ID: 16764022
[No Abstract] [Full Text] [Related]
57. Polyol pathway and diabetic peripheral neuropathy.
Oates PJ
Int Rev Neurobiol; 2002; 50():325-92. PubMed ID: 12198816
[TBL] [Abstract][Full Text] [Related]
58. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
Yagihashi S; Yamagishi SI; Wada Ri R; Baba M; Hohman TC; Yabe-Nishimura C; Kokai Y
Brain; 2001 Dec; 124(Pt 12):2448-58. PubMed ID: 11701599
[TBL] [Abstract][Full Text] [Related]
59. Aldose reductase catalysis and crystallography. Insights from recent advances in enzyme structure and function.
Petrash JM; Tarle I; Wilson DK; Quiocho FA
Diabetes; 1994 Aug; 43(8):955-9. PubMed ID: 8039602
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
Sampath C; Sang S; Ahmedna M
Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
